NeuroDerm (NDRM): Hiking PT 43% After Management Meeting - Jefferies
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Jefferies analyst, Peter Welford, reiterated his Buy rating on shares of Neuroderm Ltd (NASDAQ: NDRM) and raised his price target to $40 from $28. The analyst met management in Israel and gained confidence in the commercial potential of ND0612L/H, raising his WW peak sales to $1.75bn from $1.3bn. He is keeping a conservative 40% probability of a 2019E launch however.
On a side note, the analyst believes Sunovion's recent acquisition of peer Cynapsus illustrates the appetite for assets in Parkinson's.
Shares of Neuroderm Ltd closed at $16.08 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Cuts Price Target on ResMed (RMD) to $56 Following 1Q Miss
- Visa (V) PT Trimmed to $93 at Stifel With Initial 2017 Guidance a Touch Light
- Swift Transportation (SWFT) PT Bumped to $24 at Stifel Following Solid Q3
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Analyst PT Change, Management Comments
Related EntitiesJefferies & Co, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!